id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1445165,3b3d64e7-7e64-40cc-afcd-e78794345f22,Q3,KNIGHT CAPITOL CONSULTANTS,40036301,GENZYME CORPORATION,2013,third_quarter,HCR,"Implementation of, and possible change/repeal to provisions related to the Patient Protection and Affordable Care Act (PL 111-178) and the Reconciliation Act (PL 111-152), including implementation of biosimilars provisions and the Independent Payment Advisory Board.  General issues related to reimbursement for pharmaceuticals, including drug pricing, orphan drugs, reimbursement for pharmaceuticals under Medicare Parts B and D, and 340B clinics.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2013-10-16T19:33:34.300000-04:00